<DOC>
	<DOCNO>NCT00001048</DOCNO>
	<brief_summary>To compare safety efficacy antiretroviral therapy ( zidovudine plus either didanosine dideoxycytidine ) versus antiretroviral therapy plus intravenous cytarabine ( Ara-C ) versus antiretroviral therapy plus intrathecal Ara-C maintenance improvement neurological function 6 month HIV-infected individual develop progressive multifocal leukoencephalopathy ( PML ) . To compare effect three treatment regimen Karnofsky score MRI study . The effectiveness Ara-C treatment PML , cause human DNA papovavirus ( designate JC virus ) infection , determine , although encouraging result occur intrathecal administration drug .</brief_summary>
	<brief_title>Comparison Anti HIV Drugs Used Alone Combination With Cytosine Arabinoside Treat Progressive Multifocal Leukoencephalopathy ( PML ) HIV-Infected Patients</brief_title>
	<detailed_description>The effectiveness Ara-C treatment PML , cause human DNA papovavirus ( designate JC virus ) infection , determine , although encouraging result occur intrathecal administration drug . Patients randomize receive antiretroviral therapy alone ( AZT plus ddI ddC ) , antiretroviral therapy plus intravenous Ara-C , antiretroviral therapy plus intrathecal Ara-C. All patient receive 24 week antiretroviral therapy . Beginning week 2 , patient intravenous Ara-C arm receive daily infusion Ara-C 5 day , cycle repeat every 21 day . Patients intrathecal Ara-C arm receive single administration Ara-C week 2 , 3 , 4 , 5 , 6 , 8 , 10 , 12 , 16 , 20 , 24 . A brain biopsy confirmation situ hybridization require within 7 day study entry . Patients follow every 4 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Leukoencephalopathies</mesh_term>
	<mesh_term>Leukoencephalopathy , Progressive Multifocal</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Local intralesional chemotherapy mucocutaneous Kaposi 's sarcoma . Topical antifungal , clotrimazole , ketoconazole , fluconazole , amphotericin B treatment mucosal esophageal candidiasis . Foscarnet newly develop CMV infection , discussion protocol chair . Prophylactic maintenance therapy opportunistic infection , provide patient consider clinically stable . No 1000 mg/day acyclovir herpes simplex . Antibiotics bacterial infection clinically indicate . Antipyretics , analgesic , antiemetic . Concurrent Treatment : Allowed : Local radiation therapy mucocutaneous Kaposi 's sarcoma . Patients must : HIV infection . Confirmed PML . No current active opportunistic infection require systemic therapy . Life expectancy least 3 month . NOTE : A durable power attorney recommend severe neurologic psychiatric impairment foreseen patient study . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Current active cryptococcal meningitis , cytomegaloviral encephalitis , toxoplasmosis encephalitis , CNS lymphoma , neurosyphilis . NOTE : Patients maintenance therapy cryptococcal meningitis toxoplasmosis encephalitis stable 4 month permit . Conditions seriously increase risk surgical procedure ( e.g. , coagulopathy , severe thrombocytopenia ) . Any disease would interfere evaluation patient . Other lifethreatening complication likely cause death &lt; 3 month . Concurrent Medication : Excluded : Ganciclovir . Interferon . Systemic chemotherapy AraC ( unless specifically allow ) . Antiretroviral medication AZT , ddI , ddC . Patients follow prior condition exclude : History allergy intolerance GCSF . Prior Medication : Excluded : Any prior AraC . Excluded within 14 day prior study : Ganciclovir foscarnet . Interferon . Antiretroviral medication AZT , ddI , ddC . Experimental medication treatment PML .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Leukoencephalopathy , Progressive Multifocal</keyword>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Zalcitabine</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Granulocyte Colony-Stimulating Factor</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Injections , Spinal</keyword>
</DOC>